Hemophilia is a bleeding disorder in which the blood does not clot properly. This leads to prolonged bleeding following injuries or surgery and spontaneous bleeding. Over time, it can also lead to chronic health problems such as joint disease. However, if the disorder is managed properly, people with hemophilia can live long, healthy lives.
Often a hemophilia treatment center (HTC) is the best choice for managing hemophilia, as studies show that people with hemophilia who receive care at an HTC are 40 percent less likely to die of a hemophilia-related complication. HTCs have emerged as specialized, multidisciplinary health care centers with unique expertise to meet the physical, psychosocial and emotional needs of people with hemophilia (factor VIII or IX deficiency) or a related bleeding condition such as Factor XI deficiency, von Willebrand disease (VWD), other factor deficiencies or a defect in platelet function.
With Dr. Hagstrom as Regional Director, the Mid-Atlantic Region’s Core Center for HTCs has transitioned to LVHN after being located at the Children’s Hospital of Philadelphia (CHOP) for the last 14 years.
Founded over 30 years ago, the Hemophilia Treatment Center at Lehigh Valley Hospital (LVH)–Muhlenberg is one of approximately 150 HTCs in the United States. It’s also now a national leader in hemophilia care with the recent appointment of J. Nathan Hagstrom, MD, Physician in Chief of Lehigh Valley Reilly Children’s Hospital and Chair of Pediatrics at Lehigh Valley Health Network (LVHN), as the Regional Director for the Mid-Atlantic Region of federally funded HTCs. With Dr. Hagstrom as Regional Director, the Mid-Atlantic Region’s Core Center for HTCs has transitioned to LVHN after being located at the Children’s Hospital of Philadelphia (CHOP) for the last 14 years.